reference/8079000

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/8079000

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase III\|Journal Article\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
endingPage	546
issn	1875-8908 1387-2877
issueIdentifier	2
pageRange	535-546
publicationName	Journal of Alzheimer's disease : JAD
startingPage	535
bibliographicCitation	Russu A, Samtani MN, Xu S, Adedokun OJ, Lu M, Ito K, Corrigan B, Raje S, Liu E, Brashear HR, Styren S, Hu C. Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab. J Alzheimers Dis. 2016 May 03;53(2):535–46. doi: 10.3233/jad-151065. PMID: 27163805.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e4d706788fea1c556228ba07f4350df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_28354ea8841da7a2b6f1bcc00cdd2672 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bf0728d4906157f1deffec24ebb11a2b http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9fa5a1156cda721998821715b4c07406 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_875a7bbd88c51efd0bdb7bf9a5342566 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_67376585d2343323a84f15d05b08a333 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03f105797a0c015021499074414e070e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_915a9af3084d72e7e9585fc68cbcc346 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8bf836c0e14f45ff10103bee2bebbad4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e767211790bf29737a7421a327a7ad45 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ceb4762b2eae6fd6ea45cee47aba149 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5fcf957ab160dd955b20dc250e2f9a5e
date	2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.3233/jad-151065 https://pubmed.ncbi.nlm.nih.gov/27163805
isPartOf	https://portal.issn.org/resource/ISSN/1387-2877 https://portal.issn.org/resource/ISSN/1875-8908 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/21942
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab
discusses	http://id.nlm.nih.gov/mesh/M0021333 http://id.nlm.nih.gov/mesh/M0556300 http://id.nlm.nih.gov/mesh/M0025678 http://id.nlm.nih.gov/mesh/M0001215 http://id.nlm.nih.gov/mesh/M0023752 http://id.nlm.nih.gov/mesh/M0541585 http://id.nlm.nih.gov/mesh/M0011157 http://id.nlm.nih.gov/mesh/M0451542 http://id.nlm.nih.gov/mesh/M0001601
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000544Q000188 http://id.nlm.nih.gov/mesh/D000544Q000134 http://id.nlm.nih.gov/mesh/D061067Q000627 http://id.nlm.nih.gov/mesh/D007155Q000627 http://id.nlm.nih.gov/mesh/D015415Q000134
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000544Q000000981 http://id.nlm.nih.gov/mesh/D013844Q000378 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000814Q000378 http://id.nlm.nih.gov/mesh/D000814Q000493 http://id.nlm.nih.gov/mesh/D004311 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D019540 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D000544Q000235 http://id.nlm.nih.gov/mesh/D001057Q000235 http://id.nlm.nih.gov/mesh/D000073216 http://id.nlm.nih.gov/mesh/D013844Q000493 http://id.nlm.nih.gov/mesh/D008279 http://id.nlm.nih.gov/mesh/D016875Q000134 http://id.nlm.nih.gov/mesh/D049268
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_d22ef8d03375d89409872210d728cfc0 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6852 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2826731

Total number of triples: 65.